183.45
Iqvia Holdings Inc stock is traded at $183.45, with a volume of 1.27M.
It is down -1.84% in the last 24 hours and up +3.98% over the past month.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
See More
Previous Close:
$186.88
Open:
$187.31
24h Volume:
1.27M
Relative Volume:
0.77
Market Cap:
$30.62B
Revenue:
$16.63B
Net Income/Loss:
$1.39B
P/E Ratio:
22.74
EPS:
8.0674
Net Cash Flow:
$2.12B
1W Performance:
+0.68%
1M Performance:
+3.98%
6M Performance:
-18.77%
1Y Performance:
+24.48%
Iqvia Holdings Inc Stock (IQV) Company Profile
Name
Iqvia Holdings Inc
Sector
Industry
Phone
919-998-2000
Address
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IQV
Iqvia Holdings Inc
|
183.45 | 31.19B | 16.63B | 1.39B | 2.12B | 8.0674 |
|
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
|
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
|
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Mar-06-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Nov-13-25 | Initiated | BMO Capital Markets | Outperform |
| Nov-03-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-29-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-09-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-03-25 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Initiated | RBC Capital Mkts | Outperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-13-24 | Initiated | BTIG Research | Buy |
| Nov-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Mar-17-23 | Initiated | Truist | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Nov-17-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-29-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-16-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-08-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jul-07-20 | Initiated | Stephens | Equal-Weight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Upgrade | CFRA | Sell → Hold |
| Nov-14-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-21-19 | Upgrade | Mizuho | Neutral → Buy |
| May-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-18-19 | Upgrade | Jefferies | Hold → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Oct-02-18 | Reiterated | Robert W. Baird | Outperform |
| Jul-25-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-25-18 | Reiterated | Stifel | Buy |
| Jul-03-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-18 | Upgrade | Goldman | Neutral → Buy |
| Mar-07-18 | Upgrade | SunTrust | Hold → Buy |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
View All
Iqvia Holdings Inc Stock (IQV) Latest News
How IQVIA’s €950 Million Debt Refinancing and 2026 Outlook Update Will Impact IQVIA Holdings (IQV) Investors - Sahm
(IQV) Movement as an Input in Quant Signal Sets - Stock Traders Daily
IQVIA Holdings Prices €950 Million Senior Notes Offering - TipRanks
IQVIA prices €950M senior notes due 2033 at 4.625% - TradingView
€950M IQVIA (NYSE: IQV) senior notes due 2033 for refinancing debt - Stock Titan
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
IQVIA prices €950 million senior notes due 2033 By Investing.com - Investing.com Nigeria
IQVIA (IQV) Up 3.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
IQVIA prices €950 million senior notes due 2033 - Investing.com
IQVIA Announces Pricing of Senior Notes - Business Wire
IQVIA unit announces senior notes offering - MSN
IQVIA Holdings earnings preview: What to expect - MSN
Barclays upgrades IQVIA stock rating on scale, execution strength - Investing.com
IQVIA Holdings Inc. (IQV) Announces €950 Million Senior Notes Of - GuruFocus
HSBC Adjusts Price Target on IQVIA to $210 From $240, Maintains Buy Rating - Moomoo
IQVIA Announces €950 Million Senior Notes Offering - TipRanks
IQVIA to raise €950M via 2033 senior notes to refinance debt - TradingView
€950M IQVIA (NYSE: IQV) senior notes planned to refinance debt - Stock Titan
IQVIA Holdings Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
IQVIA Holdings (IQV) Plans €950M Senior Notes Offering for Debt Refinancing - GuruFocus
IQVIA Announces Offering of Senior Notes - 01net
IQVIA plans €950 million senior notes offering due 2033 - Investing.com UK
IQVIA to Raise $1.10 Billion in Debt Offering - marketscreener.com
IQVIA plans €950 million senior notes offering due 2033 By Investing.com - Investing.com Canada
Inside IQVIA’s €950M notes plan to refinance existing debt - Stock Titan
Is IQVIA Holdings Inc (IQV) a Bargain After 3.3% Drop? GF Value Says Undervalued - GuruFocus
IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Here's why IQVIA Holdings (IQV) is a strong value stock - MSN
IQVIA Holdings, Inc. (IQV) Stock Analysis: A 25% Upside Potential Amid Strong Analyst Ratings - DirectorsTalk Interviews
Are Wall Street analysts predicting IQVIA Holdings stock will climb or sink? - MSN
Is It Too Late To Consider Buying IQVIA Holdings Inc. (NYSE:IQV)? - Yahoo Finance
CNIL fines IQVIA €5M for health data warehouse breaches - PPC Land
IQVIA Holdings Hits Day High with 9.34% Surge in Strong Intraday Performance - Markets Mojo
Veeva vs. IQVIA: Which Life Sciences Tech Stock Holds More Promise? - Yahoo Finance
IQVIA Holdings Inc stock (US46266C1053): shares advance after recent outlook hike and buyback suppor - AD HOC NEWS
IQVIA Holdings Inc (IQV) Stock Up 9.3% and Still Undervalued -- GF Score: 84/100 - GuruFocus
IQV News | IQVIA HOLDINGS INC (NYSE:IQV) - ChartMill
IQVIA Rose 6% This Week. Here’s How Much the Stock Could Rise in 2026 - TIKR.com
IQVIA Jumps 9.3% as Investors Refocus on Raised 2026 Profit Outlook and Buyback Support - Moomoo
IQVIA jumps 9.3% as investors refocus on raised 2026 profit outlook and buyback support - Quiver Quantitative
IQVIA Holdings Jumps 5.7% Amid Sector-Wide Rally - AlphaStreet
Here's Why Investors Must Hold IQV Stock in Their Portfolios for Now - TradingView
Analysts Are Bullish on Top Healthcare Stocks: IQVIA Holdings (IQV), Lantheus (LNTH) - The Globe and Mail
IQVIA CEO to Speak at Jefferies Global Healthcare Conference 2026 - BioSpace
IQVIA Holdings Inc (IQV) Stock Down 3.5% -- Now Undervalued? GF Score: 86/100 - GuruFocus
IQVIA CEO to Speak at Jefferies Global Healthcare Conference - pharmiweb.com
Iqvia Holdings Inc Stock (IQV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):